Table 1.
Articles included in the paper.
| Reference | PS(TS)/SS | Type of bone (%) | ABW (mm) | ABH (mm) | ME (%) | MR & IP (months) | BR (%) | Impl (n°) | Success (%) | Surv (%) | Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Von Arx et al. 1996 | 20(20)/20 | AB (100) | ID | ID | 50 | 4.7 | 10 | 28 | ID | ID | ID |
|
| |||||||||||
| Malchiodi et al. 1998 | 25(25)/25 | AB (100) | 5.65 | ID | 0 | 8 (IP time zero) | ID | 120 | 100 (8 month) | 97.5 | |
|
| |||||||||||
| Maiorana et al. 2001 | 14(14)/23 | AB/ABB (50/50) | ID | ID | 14.2 | 5 | ID | 59 | 98.3 | 100 (48 month) | 5 months |
|
| |||||||||||
| Artzi et al. 2003 | 10(10)/10 | ABB (100) | ID | 5.2 (9 month) | 20 | 9 | 18.8 ± 7.98 | 20 | 100 | 100 (24 month) | 24 months |
|
| |||||||||||
| Rocuzzo et al. 2004 | 18(18)/18 | AB (100) | ID | 4.8 | 17.3 | 4.6 | ID | 37 | 100 | 100 | 6 months |
|
| |||||||||||
| Proussaefs and Lozada 2006 | 17(17)/17 | AB/ABB (50/50) | 3.88 (6 month) | 2.59 (6 month) | 35.3 | 8.47 | 15.11 (6 month) | 41 | ID | ID | |
|
| |||||||||||
| Corinaldesi 2007 | 6(12)/6 (control group) | AB (100) | ID | 4.17 | 0 | 8.6±0.51 | ID | 17 | 100 | 100 | 12 months |
| 6(12)/6 (test group) | AB/ABB (70/30) | ID | 4 | 0 | 8.6±0.51 | ID | 18 | 100 | 100 | 12 months | |
|
| |||||||||||
| Rocuzzo et al. 2007 | 12**(23)/12 (control group) | AB (100)* (no Ti-mesh) | ID | 5.5 | NO MESH | 4.7 | 34.5 | ID | ID | ID | |
| 12**(23)/12 (test group) | AB (100) (with Ti-mesh) | ID | 5.7 | 33.3 | 4.6 | 13.5 | ID | ID | ID | ||
|
| |||||||||||
| Louis et al. 2008 | 44(44)/45 | AB (100) | ID | 13.7 | 52.27 | 6.9 | ID | 174 | ID | 100 (17 months) | |
|
| |||||||||||
| Pieri et al. 2008 | 16(16)/19 | AB/ABB (70/30) | 4.16 ± 0.59 | 3.71 ± 1.24 | 5.3 | 8–9 | ID | 44 | 100 | 100 (24 months) | |
|
| |||||||||||
| Corinaldesi 2009 | 13(24)/13 | AB (100) | ID | 5.4 ± 1.81 | 23 | 0 | ID | 20 | 96.4%. | 100 | |
| 11(24)/14 | AB (100) | ID | 4.5 ± 1.16 | 7 | 8–9 | ID | 36 | 96.4%. | 100 | ||
|
| |||||||||||
| Torres et al. 2010 | 15(30)/21 (control group) | ABB (100) | 3.7 ± 0.6 (6 months) | 3.1 ± 0.8 (6 months) | 28.5 | 6 | 22.6 | 46 | 97.3 | 100 | |
| 15(30)/22 (test group) | ABB (100) + PrP | 4.1 ± 0.6 (6 months) | 3.5 ± 0.7 (6 months) | 0 | 6 | 14.3 | 51 | 100 | 100 | ||
|
| |||||||||||
| Miyamoto et al. 2011 | 41(41)/50 | AB (100) | 4.3 ± 2.0 | 8.1 ± 4.8 | 36 | 6 | 8 | 87 | 98 | 92.8 | |
|
| |||||||||||
| Khamees et al. 2012 | 8(16)/16 (control group) | AB(100) | 3.44 ± 0.54 | ID | 4 | ID | 43.62 | 59 | ID | ID | |
| 8(16)/16 (test group) | AB/ABB (50/50) | 2.88 ±0.57 | ID | ID | 36.65 | ID | ID | ||||
Note. TS, total specimen; PS, partial specimen; SS, surgical site; ID, insufficient data; ABW, average bone weight gained; ABH, average bone height gained; ME, bone exposure; AB, autologous bone; ABB, bovine bone; MR and IP, time of mesh removed and implant placed; BR, bone resorption under Ti-mesh; Impl, implant number; Surv, implant survival; Success, implant success;
*
bone block graft;
**
1 patient subdued with both treatment (control/test)